Responses
Regular and Young Investigator Award Abstracts
Combination Immunotherapies
869 Venetoclax, a specific BCL-2 inhibitor, modulates CAR T cells genetically and functionally during production and augments their anti-tumor response
Compose a Response to This Article
Other responses
No responses have been published for this article.
